Jinling Pharmaceutical (000919): Twenty years of forging ahead with “medicine+medical care” two-wheel drive
Jinling Pharmaceutical (000919) Semi-Annual Report Review: Stable Growth in Medical Services, Performance Slightly Lower Expectations
Comments on the quarterly report of Jinling Pharmaceutical Co., Ltd. (000919): sustained and steady growth of income, gross profit and expenses affect performance
[Guolian Securities] Jinling Pharmaceutical Industry: sustained and steady growth of income, gross profit and expenses affect performance
Comments on Jinling Pharmaceutical Industry (000919): there is a broad space for strengthening core resources investment in medical services.
Jinling Pharmaceutical Industry (000919) comments: medical service price reform gives the company more room for development
Comments on the annual report of Jinling Pharmaceutical Industry (000919): Mailuoning pressure continues to decline and medical services develop steadily
[Guolian Securities] comments on Jinling Pharmaceutical Annual report: Mailuoning pressure continues to decline, and medical services develop steadily.
Comments on the quarterly report of Jinling Pharmaceutical Industry (000919): pharmaceutical business is under pressure and medical services are growing rapidly.
Comments on Jinling Pharmaceutical Industry (000919): the model of "Jinling + Gulou" has achieved remarkable results.
Comments on Jinling Pharmaceutical Industry (000919): "Suqian Model" effectively replicates the rapid growth of medical services
[Southwest Securities] Jinling Pharmaceutical: The “Suqian Model” Is Effectively Replicated, and Medical Services Are Growing Rapidly
【瑞银证券】金陵药业:看好公司医疗服务业务“金陵+鼓楼”模式
【兴业证券】金陵药业:业绩稳定增长,关注医疗服务发展
【华泰证券】金陵药业:安庆医院收购落地,医疗服务继续加速
【华创证券】金陵药业:金鼓模式继续复制,安庆医院改善空间可期
【光大证券】金陵药业:“金陵+鼓楼”模式稳固,医疗服务持续发展
【华泰证券】金陵药业:药品业务稳健筑底,医疗服务持续可期
【宏源证券】金陵药业:成本控制提升利润,长期前景看好
金陵药业(000919)深度报告:金鼓模式复制性强 外延扩张可期
No Data